CAMBRIDGE, Mass., Dec. 1, 2014 /PRNewswire/ -- NextCODE Health, which provides the most proven system for applying genome sequence data to deliver better medicine, today announced the appointment of Dr C Thomas Caskey as senior vice president for medical science and diagnostics. Dr Caskey, who is professor of molecular and human genetics at Baylor School of Medicine and founder of its Medical Genetics Laboratories, will also serve as the founding member and chair of NextCODE's scientific advisory board.
"Sequencing has been solved, and NextCODE's technology has all of the capabilities needed to bring that data swiftly into widespread clinical use," Dr Caskey said. "That means a data architecture that can rapidly deliver analysis at scale, accurate diagnosis, and interpretation backed by the best reference sets. Only NextCODE does all that today, and my task is to help get these capabilities into the hands of the institutions and doctors around the world who are using genomics to improve patient outcomes."
"We are thrilled to welcome Tom on board at such an exciting point in the growth of our business and in the medical application of genomics that he has pioneered," said Jeffrey Gulcher, MD, PhD, president and CSO of NextCODE. "Tom's leadership runs from pathbreaking gene discovery through clinical genomics and drug development. His scientific and medical insight will be invaluable across the full range of fields in which our technology promises to advance better healthcare."
Dr Caskey is board certified in internal medicine, medical genetics and molecular genetics. He is a member of the Institute of Medicine of the National Academy of Sciences and fellow of the Royal Society of Canada. He has served as president of the Human Genome Organization, the American Society of Human Genetics and the Academy of Medicine, Engineering and Science of Texas. Dr Caskey's previous appointments include research posts at NIH as well as five years at Merck as senior vice president, research and president of the Merck Genome Research Institute.
NextCODE puts the world's most proven sequence analysis platform in the hands of clinicians and researchers around the globe, enabling them to use the full power of NGS data to better diagnose and treat disease. Our solutions combine the only whole-genome analysis system developed at population scale with access to the largest clinical genetics reference database in the world. That gives our partners the ability to solve more cases more efficiently, to store, analyze, visualize and collaborate using all their data – at base-by-base resolution, in real time, from any browser. NextCODE is a private company co-founded by former deCODE genetics executives Jeffrey Gulcher and Hannes Smarason and headquartered in Cambridge, Massachusetts. www.nextcode.com
+1 781 775 6206
SOURCE NextCODE Health